Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix? - 24/03/22
Doi : 10.1016/S1473-3099(22)00178-5
Edward P K Parker a, b 
, Shalini Desai a, Melanie Marti a, Katherine L O’Brien a, David C Kaslow e, Sonali Kochhar f, g, Folake Olayinka h, Alejandro Cravioto i, Hanna Nohynek j, Joachim Hombach a, Annelies Wilder-Smith a, c, d
, Shalini Desai a, Melanie Marti a, Katherine L O’Brien a, David C Kaslow e, Sonali Kochhar f, g, Folake Olayinka h, Alejandro Cravioto i, Hanna Nohynek j, Joachim Hombach a, Annelies Wilder-Smith a, c, d a Immunization, Vaccines and Biologicals, WHO, Geneva, Switzerland
b The Vaccine Centre, London School of Hygiene &Tropical Medicine, London, UK
c Institute of Social and Preventive Medicine, University of Berne, Berne, Switzerland
d Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany
e PATH Essential Medicines, PATH, Seattle, WA, USA
f Global Healthcare Consulting, New Delhi, India
g Department of Global Health, University of Washington, Seattle, WA, USA
h STAR Program, Public Health Institute, Washington DC, USA
i Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico
j Department of Health Security at the Finnish Institute for Health and Welfare, Helsinki, Finland
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
© 2022
Elsevier Ltd. Tous droits réservés.
Vol 22 - N° 4
P. 438-440 - avril 2022 Retour au numéro
Article précédent
- Pharyngeal screening for Chlamydia trachomatis, more harm than good?
- Alje P van Dam, Henry J C de Vries
- COVID-19 vaccine results might inform malaria vaccine strategies
- Movin Abeywickrema, Anna L Goodman
Bienvenue sur EM-consulte, la référence des professionnels de santé.